ARA-290 – 10mg

Description

ARA-290 (also known as Cibinetide) is a synthetic 11-amino acid peptide engineered from the helix-B surface domain of erythropoietin (EPO). Designed to capture EPO’s tissue-protective properties without stimulating red blood cell production, it selectively activates the Innate Repair Receptor (IRR). Clinical and preclinical research highlights its potential for neuroprotection, anti-inflammatory signaling, and nerve regeneration. Currently for research use only.

PURITY

99% HPLC

RUO

Research Use Only
Not for human or veterinary use.

Price: $60.00

Highlights
  • Innate Repair Receptor (IRR) Activation — Selectively binds the IRR — a cell surface complex found on nerve, immune, and vascular cells — triggering localized tissue-protective and anti-inflammatory signaling without engaging EPO’s hematopoietic pathway.
  • Neuroprotection & Nerve Regeneration — Preclinical and early clinical studies show ARA-290 may reduce neuropathic pain, support corneal nerve fiber regeneration, and promote functional recovery following peripheral nerve injury — with particular interest in diabetic and sarcoidosis-related neuropathy.
  • Targeted Anti-inflammatory Action — Rather than broadly suppressing immunity, ARA-290 rebalances local inflammatory responses — reducing pro-inflammatory cytokines and shifting immune cells toward a tissue-repair profile, with reductions in markers like CRP observed in small trials.
  • Safe EPO-Derived Profile — By isolating EPO’s protective domain while eliminating sequences responsible for erythropoiesis, ARA-290 avoids the cardiovascular risks of EPO therapy (hypertension, thromboembolism) while retaining its regenerative benefits, with high subcutaneous bioavailability (>85%).
Related products

Age verification

This website contains information about supplementary products. By entering, you confirm that you are of legal age (18 years or older) to access this information. If you are not of legal age, please leave this site immediately.